Showing the latest 10 filings. Sign in to filter or browse the full history.
10 of 25 filings·Updated 15 Aug 2026
Showing 10 of 25 filings.
15 Aug 20261 filing
Company UpdateNewspaper Publication

Announcement under Regulation 30 (LODR) - Newspaper Publications

Filed 16:46View Source
13 Aug 20263 filings
AGM/EGMAGM

Hemo Organic to hold 34th AGM via VC/OAVM on Sept 8, 2026; ordinary business on accounts and auditors

AGM Details

  • 34th AGM on Sep 8, 2026 at 3:00 PM IST via VC/OAVM.
  • Record date for voting: Sep 1, 2026.
  • Remote e-voting: Sep 5–7, 2026.
  • Book closure: Sep 1–8, 2026 (inclusive).

Resolutions Put to Vote (Ordinary)

  • Adoption of audited financial statements and reports thereon.
  • Re-appointment of Murlidhar Joshi as Director retiring by rotation.
  • Appointment of M/s V S S B & Associates as Auditors for five years; remuneration to be fixed.

Voting Results

  • Voting results to be announced after Scrutinizer’s report.
  • Scrutinizer appointed to oversee the electronic voting process.

Dividend

  • No dividend proposed or declared for FY2025-26.

Director & KMP Changes

  • Deepak Rochani appointed Additional Non-Executive Independent Director on June 27, 2025.
  • Regularized by shareholders as Director on Sep 29, 2025.
  • Resigned as Non-Executive Independent Director on Mar 31, 2026.
  • Murlidhar Joshi to be reappointed as Director retiring by rotation.
  • Garima Dineshkumar Jain resigned as Company Secretary on Jun 23, 2025.
  • Yukta Prakash Patel appointed Company Secretary on Jun 27, 2025.

Auditor Appointments

  • Previous auditor M/s M A A K & Associates ceased post AGM.
  • M/s V S S B & Associates appointed Statutory Auditors for five years.
  • Remuneration to be fixed by Audit Committee/Board.

Material Related Party Transactions

  • Related party transactions with KMP are at arm’s length and in the ordinary course.
  • RPT disclosures filed with stock exchanges; RPT policy on company website.

Other Material Approvals

  • 33rd AGM: Regularize Rochani as Non-Executive Director; borrowing limits; sale of undertakings; loans to Directors.
  • EGM (Jan 7, 2026): increase in authorised share capital.
  • EGM: issue of warrants to non-promoter category on a preferential basis.
  • EGM: in-principal approval for warrants from BSE; allotment of 3,400,000 warrants to non-promoter category.
  • EGM: shift registered office within the same city; Rochani resignation from NED.
Filed 19:29View Source
Company UpdateAppointment of Statutory Auditor/s

Appointment of Statutory Auditor

Filed 19:25View Source
Company UpdateRetirement

Statutory Auditor completes maximum tenure; not eligible for reappointment

Auditor retirement

  • Statutory Auditor: M/s M A A K & Associates, Chartered Accountants (FRN 135024W).
  • Reason: Completion of tenure under Companies Act, 2013; maximum permissible tenure reached.
  • Effective date: From the conclusion of the 34th AGM, 8 September 2026.
  • Not eligible for re-appointment for a further term.
Filed 19:19View Source
16 Jul 20261 filing
Company UpdateNewspaper Publication

Submission of Newspaper Advertisement of extract of Un-audited financials results for the quarter ended on 30th June, 2026

Filed 14:09View Source
15 Jul 20262 filings
ResultFinancial Results

Hemo Organic reports no deviation in use of proceeds from convertible warrants; Rs 106.25 lakh upfront

Proceeds utilization & results filing

  • Date of allotment: 26 February 2026.
  • Upfront proceeds received: Rs 106.25 lakh (25%).
  • 34,00,000 warrants issued at Rs 12.50 each.
  • Working Capital upfront allocation: Rs 79.69 lakh.
  • General Corporate upfront allocation: Rs 26.56 lakh.
  • Utilised till 30 June 2026: Working Capital Rs 79.69 lakh.
  • Utilised till 30 June 2026: General Corporate Rs 25.71 lakh.
  • Total unutilised funds as of 30 June 2026: Rs 0.85 lakh.
  • Balance 75% of issue price payable on exercise/conversion.
  • Warrants exercisable within 18 months from allotment.
  • Allotment to Non-Promoter investors.
  • Un-audited financial results for quarter ended 30 June 2026 submitted.

Audit confirmation

  • Audit Committee reviewed the deviation statement on 15 July 2026.
  • Auditors MAAK & Associates certify no deviation in utilization.
Filed 17:59View Source
ResultFinancial Results

Hemo Organic Board approves unaudited quarter ended 30 June 2026 results with Limited Review

Board actions

  • Board approved unaudited quarterly results for quarter ended 30 June 2026, with Limited Review Report.
  • Results prepared under Regulation 33 of SEBI LODR.
  • Meeting held on 15 July 2026, from 04:00 PM to 05:15 PM.
  • Board also transacted other business as per circulated agenda.
Filed 17:46View Source
10 Jul 20262 filings
Board Meeting

Hemo Organic to hold board meeting on 15 July 2026 to review unaudited Q1 results

Meeting Details

  • Board meeting scheduled for 15 July 2026 at 4:00 p.m.; location not disclosed.

Key Agenda Items

  • Consider and approve unaudited quarterly results for quarter ended 30 June 2026, with Limited Review Report.
  • To transact other business as per circulated agenda.

Other Notes

  • Trading window closure periods not disclosed.
Filed 18:44View Source
Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Dematerialisation processing, listing of dematerialised securities, and certificate mutilation/cancellation confirmed

Dematerialisation processing and certificate handling

  • Securities received for dematerialisation were processed and confirmed to depositories.
  • Dematerialised securities have been listed on the stock exchanges where the earlier securities are listed.
  • Physical certificates were mutilated and cancelled after verification; the depository's name was substituted within 15 days.
Filed 17:04View Source
25 Mar 20261 filing
Insider Trading / SASTClosure of Trading Window

Intimation of Closure of Trading window

Filed 17:04View Source
Showing 10 of 25 filings